Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
There are very limited reports about childhood acute promyelocytic leukemia (APL), especially about arsenic trioxide (ATO) treatment in both induction and post-remission regimens. 35 newly diagnosed APL patients received ATO treatment in our center and the clinical course as well as the outcome of them was investigated. The dose of intravenous ATO was 0.15-0.17 mg/kg per day, only one patient got 0.33 mg/kg per day, maximum dose was 10 mg per day in induction therapy with minimal chemotherapy treatment (CT) for hyperleukocytosis. Anthracycline or anthracycline-based CT was used for consolidation therapy and followed by 0.10-0.15 mg/kg per day ATO treatment in maintenance therapy. The continuous detection for morphology of bone marrow and PML-RARa were necessary for administrating CT or not. 3 patients died during induction therapy for intracranial hemorrhage, leukocytosis and septic shock. Total of 30 patients achieved complete remission (CR) and were followed-up for 10-108 months. The overall survival (OS) for all patients was 82.7%, whereas the OS for patients obtained CR was 95.8%. The event-free survival for 5 years was 80.3%. Disseminated intravascular coagulation could be under control to reduce induction mortality with adequate supportive care, especially in the first 2 weeks. The side effects of ATO were mild and transient. This regimen of ATO treatment both in induction and post-remission therapy was effective and safe for childhood APL to get long-term survival.
Wang
Hong
H
Pediatric Hematology/Oncology Department, Hematology Center, ShengJing Hospital of China Medical University, Sanhao Street #36, Heping District, Shenyang, 110004, Liaoning, China. wang_hong354@hotmail.com
Hao
Liangchun
L
Wang
Xiuli
X
Li
Jiate
J
Wu
Qiong
Q
Bian
Shuang
S
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D004211:Disseminated Intravascular Coagulation / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide
Leuk Res. 2007 Jun;31(6):765-71
17007927
Blood. 2005 Jul 15;106(2):447-53
15677559
Hematology Am Soc Hematol Educ Program. 2008;:391-9
19074116
J Clin Oncol. 2004 Apr 15;22(8):1404-12
15084614
Pediatr Blood Cancer. 2008 Aug;51(2):210-5
18428427
Hematology Am Soc Hematol Educ Program. 2003;:82-101
14633778
Blood. 1999 Nov 15;94(10):3315-24
10552940
Blood. 2001 Sep 1;98(5):1633; author reply 1633-4
11547772
Blood. 2002 Dec 15;100(13):4298-302
12393590
Leukemia. 2004 Oct;18(10):1587-90
15356649
Blood. 2008 Mar 1;111(5):2505-15
18299451
Eur J Haematol. 2009 Nov;83(5):391-405
19563518
Blood. 2008 Jan 15;111(2):566-73
17959855
Blood. 2006 Apr 1;107(7):2627-32
16352810
J Clin Oncol. 2005 Oct 20;23(30):7632-40
16234524
Science. 2010 Apr 9;328(5975):240-3
20378816
Blood. 1981 Jun;57(6):1000-4
6939451
Semin Thromb Hemost. 2007 Jun;33(4):330-8
17525890
Ann Oncol. 2006 Jan;17(1):131-4
16227315
Blood. 1996 Aug 1;88(3):1052-61
8704214
Blood. 1973 Apr;41(4):489-96
4510926